PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
Based on a clinical study BCIRG 001 (Martin M., Mackey J., Pienkowski T.) and as an outcome of Markov simulation it was determined that the use of 6DAC for adjuvant therapy in 10 year horizon of research allows to increase the disease-free survival by 6,09%, and overall survival by 5,88% comparing t...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
IRBIS LLC
2015-03-01
|
| Col·lecció: | Фармакоэкономика |
| Matèries: | |
| Accés en línia: | https://www.pharmacoeconomics.ru/jour/article/view/79 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|